entertainment -WSS

entertainment

author：entertainment 2025-10-01 18:03:39 - browse：1

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： KalVista pill reduced swelling 'attacks' caused by genetic disease

knowledge

WSS

Time to name cancers by genetics, not organ of origin, expert says

Vertigo drug brings hope for rare neuron disorder, Niemann

Key House Republican on health care plans exit from Congress

Vaccine advisory panel ACIP left half staffed by HHS

Quicker fix for pulse oximeters urged during FDA public meeting

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare proposal to cover medical devices draws a mixed reaction

Some dementia cases could be undiagnosed liver disease

Medicare details structure of new drug price negotiation program

Novo Nordisk to expand supply of Wegovy for U.S. patients

Medicare proposal to cover medical devices draws a mixed reaction

How digital tools helped lower hypertension in marginalized patients

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare threatens to cut off funding for HCA's Mission hospital

Apple is now the first public company to be valued at $3 trillion

Industry veterans launch new biotech VC with $310M

hotspot

The dental labor crisis is a moment of opportunity

A disappointing year of Humira biosimilars

'Revelatory' study finds a smoking impact that remains after quitting

SAMSHA loosens regulations on methadone treatment centers

New Ultima Genomics DNA sequencer can read genome for $100

Key House Republican on health care plans exit from Congress

knowledge

explore

hotspot

focus